$599

Novo Partners with Valo Health for CVD and Evotec for Cardiometabolic Drug Discovery Accelerator; Zucara Doses First Patient in Ph2a ZONE Trial; Merck Initiates Efinopegdutide Study in Hepatic Impairment; Senseonics Completes Adult Arm of ENHANCE Pivotal Study; NeuroBo Posts Ph2 DA-1241 Trial in NASH to CT.gov

A series of cardiometabolic-related news items have been observed from Novo, Zucara, Merck, and NeuroBo. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here